Bundibugyo Ebolavirus: Symptoms, Causes & Treatment
Bundibugyo ebolavirus (BDBV) is a rare and highly dangerous species of the genus Ebolavirus that causes severe hemorrhagic fever in humans.
Things worth knowing about "Bundibugyo ebolavirus"
Bundibugyo ebolavirus (BDBV) is a rare and highly dangerous species of the genus Ebolavirus that causes severe hemorrhagic fever in humans.
What is Bundibugyo Ebolavirus?
Bundibugyo ebolavirus (abbreviated BDBV) is one of several distinct species within the genus Ebolavirus, belonging to the family Filoviridae. It was first identified in 2007 during an outbreak in the Bundibugyo District of western Uganda. BDBV causes Ebola virus disease (EVD), a life-threatening illness characterized by severe hemorrhagic fever and high mortality rates.
Discovery and Classification
In the autumn of 2007, an outbreak of a severe hemorrhagic illness emerged in the Bundibugyo region of Uganda. Genomic sequencing confirmed that the causative agent was a previously unknown ebolavirus species. Bundibugyo ebolavirus was subsequently classified as the fifth species of the genus Ebolavirus. It shares genetic similarities with Tai Forest ebolavirus but is genetically distinct from other species such as Zaire ebolavirus and Sudan ebolavirus.
Causes and Transmission
Like other ebolaviruses, BDBV is primarily transmitted through direct contact with the bodily fluids of infected individuals or animals. Key transmission routes include:
- Direct contact with blood, saliva, urine, feces, or other bodily fluids of infected persons
- Contact with infected animals, particularly bats and non-human primates (zoonotic transmission)
- Unsafe burial practices involving direct contact with the deceased
- Nosocomial (healthcare-associated) transmission in settings with inadequate infection control
The exact natural reservoir of Bundibugyo ebolavirus has not been definitively identified, but fruit bats of the family Pteropodidae are considered the most likely reservoir hosts, as is the case with other ebolavirus species.
Symptoms
The incubation period ranges from 2 to 21 days. Clinical manifestations of BDBV infection typically include:
- Sudden onset of high fever
- Severe headache and muscle pain
- Nausea, vomiting, and diarrhea
- Skin rash
- Impaired kidney and liver function
- In severe cases: internal and external bleeding (hemorrhagic manifestations)
Compared to Zaire ebolavirus, BDBV is considered somewhat less lethal, though the case fatality rate was approximately 25–36% during the 2007 outbreak, which remains extremely high.
Diagnosis
Clinical symptoms are initially non-specific and may overlap with other tropical infectious diseases. Laboratory-based diagnostic methods are therefore essential:
- RT-PCR (reverse transcriptase polymerase chain reaction): detects viral RNA in blood samples
- ELISA: detects viral antigens or antibodies against the virus
- Virus isolation under BSL-4 conditions (the highest biosafety level)
All diagnostic samples must be handled and transported under strict biosafety protocols.
Treatment
There is currently no specifically approved treatment for Bundibugyo ebolavirus infection. Management is primarily supportive and symptomatic:
- Intravenous fluid replacement and electrolyte management
- Treatment of secondary infections
- Intensive care support in severe cases
Therapeutic agents and monoclonal antibodies developed against Zaire ebolavirus (such as atoltivimab/maftivimab/odesivimab) may not provide full cross-protection against BDBV, highlighting the need for broadly effective treatment approaches. Similarly, approved vaccines such as rVSV-ZEBOV are primarily targeted against Zaire ebolavirus and may not offer adequate protection against BDBV.
Epidemiology and Known Outbreaks
Bundibugyo ebolavirus has been responsible for two documented outbreaks to date:
- Uganda 2007–2008: The first outbreak occurred in Bundibugyo District, with 149 confirmed and probable cases and 37 deaths.
- Democratic Republic of the Congo 2012: An outbreak in Orientale Province resulted in 57 cases and 29 deaths.
While BDBV outbreaks have been smaller in scale than those caused by Zaire ebolavirus, they represent a serious public health threat due to the high case fatality rate and the absence of a targeted therapy.
Prevention
As no specifically effective vaccine against BDBV is currently available, prevention relies on:
- Strict adherence to infection prevention and control measures (personal protective equipment, PPE)
- Isolation of confirmed or suspected cases
- Safe burial practices
- Community education and awareness in at-risk regions
- Robust surveillance systems and rapid outbreak response by public health authorities
References
- Towner JS et al. - Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens. 2008;4(11):e1000212.
- World Health Organization (WHO) - Ebola virus disease. Fact Sheet. WHO, Geneva, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
- Centers for Disease Control and Prevention (CDC) - Known Cases and Outbreaks of Ebola Virus Disease. CDC, Atlanta, 2023. Available at: https://www.cdc.gov/vhf/ebola/history/chronology.html
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categorySkull base
Myelopathy
Bundibugyo virus
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Bundibugyo ebolavirus